Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Tandem Diabetes Care (TNDM)

Tandem Diabetes Care adds Sandra Beaver, former Evolus CFO, to board of directors

Neutral Impact 2 of 5 leadership Written later

Tandem Diabetes Care appointed Sandra Beaver as an independent director effective November 7, 2025, expanding the board from eight to nine members. She will serve on the Audit Committee and the Cybersecurity and Data Privacy Committee, and the filing describes her as a finance executive with more than 20 years of experience.

Key points

  • Sandra Beaver, age 48, appointed to the board effective November 7, 2025, with a term expiring at the 2026 annual meeting
  • Initial RSU award for 20,242 shares valued at $300,000 under the non-employee director policy
  • Annual retainer of $60,000 plus $11,000 for Audit Committee and $6,000 for Cybersecurity and Data Privacy Committee service

The filing

CompanyTandem Diabetes Care (TNDM)
Form8-K, current report
Filed with the SECNov 12, 2025, 9:02 AM ET
Accession number0001438133-25-000190

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 12, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.